ENTRY       D09207                      Drug
NAME        Catumaxomab (INN);
            Removab (TN)
REMARK      ATC code: L01FX03
EFFICACY    Antineoplastic, Anti-CD3 antibody, Anti-EpCAM antibody
  DISEASE   Malignant ascites
  TYPE      Monoclonal antibody, bispecific trifunctional antibody
TARGET      EPCAM (CD326) [HSA:4072] [KO:K06737]
            CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  PATHWAY   hsa04640(915+916+917)  Hematopoietic cell lineage
            hsa04660(915+916+917)  T cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX03 Catumaxomab
                  D09207  Catumaxomab (INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               CAMs
                EPCAM (CD326)
                 D09207  Catumaxomab (INN)
              Other cell surface molecules
               CD molecules
                CD3
                 D09207  Catumaxomab (INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09207
DBLINKS     CAS: 509077-98-9
            PubChem: 96025887
///
